Timothy P. Clackson - 01 Mar 2023 Form 4 Insider Report for Theseus Pharmaceuticals, Inc.

Reporting relationship: President and CEO, Director
Issuer ticker: N/A
Reported as of: 01 Mar 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Mar 2023, 06:00:16 UTC
Prior SEC filing: 21 Feb 2023
Next SEC filing: 21 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ Bradford Dahms - Attorney-in-Fact

Key filing fact

Timothy P. Clackson filed Form 4 for Theseus Pharmaceuticals, Inc. on 02 Mar 2023.

Key facts

This page summarizes Timothy P. Clackson's Form 4 filing for Theseus Pharmaceuticals, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 02 Mar 2023, 06:00.

Change

Previous filing in this sequence was filed on 21 Feb 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

THRX transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +45,625
Change %
Price: $0.000000
Shares after: 45,625
Date: 01 Mar 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 45,625
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested.

Footnote F2

The RSUs are subject to a service-based vesting requirement, which shall be satisfied over a four-year period with 25% of the RSUs vesting on March 1, 2024 and 1/16th of the RSUs vesting quarterly thereafter, subject to the Reporting Person's continuous service with the issuer. The RSUs have no expiration date.